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Gastrointestinal (GI) side-effects of chemotherapy present a constant impediment
to efficient and tolerable treatment of cancer. GI symptoms often lead to dose
reduction, delays and cessation of treatment. Chemotherapy-induced nausea, bloating,
vomiting, constipation, and/or diarrhea can persist up to 10 years post-treatment. We
have previously reported that long-term 5-fluorouracil (5-FU) administration results in
enteric neuronal loss, acute inflammation and intestinal dysfunction. In this study, we
investigated whether the cytoprotectant, BGP-15, has a neuroprotective effect during
5-FU treatment. Balb/c mice received tri-weekly intraperitoneal 5-FU (23 mg/kg/d)
administration with and without BGP-15 (15 mg/kg/d) for up to 14 days. GI transit
was analyzed via in vivo serial X-ray imaging prior to and following 3, 7, and
14 days of treatment. On day 14, colons were collected for assessment of ex vivo
colonic motility, neuronal mitochondrial superoxide, and cytochrome c levels as
well as immunohistochemical analysis of myenteric neurons. BGP-15 did not inhibit
5-FU-induced neuronal loss, but significantly increased the number and proportion of
choline acetyltransferase (ChAT)-immunoreactive (IR) and neuronal nitric oxide synthase
(nNOS)-IR neurons in the myenteric plexus. BGP-15 co-administration significantly
increased mitochondrial superoxide production, mitochondrial depolarization and
cytochrome c release in myenteric plexus and exacerbated 5-FU-induced colonic
inflammation. BGP-15 exacerbated 5-FU-induced colonic dysmotility by reducing the
number and proportion of colonic migrating motor complexes and increasing the
number and proportion of fragmented contractions and increased fecal water content
indicative of diarrhea. Taken together, BGP-15 co-treatment aggravates 5-FU-induced
GI side-effects, in contrast with our previous findings that BGP-15 alleviates GI
side-effects of oxaliplatin.
Keywords: chemotherapy, enteric neurons, 5-fluorouracil, BGP-15, neuroprotection, cytoprotection
Abbreviations: AP-1, activator protein-1; ChAT, choline acetyltransferase; CMMC, colonic migrating motor complex;
CRC, colorectal cancer; DMSO, dimethyl sulfoxide; ENS, enteric nervous system; FC, fragmented contraction; FOLFIRI,
5-fluorouracil, irinotecan, and leucovorin; FOLFOX, 5-fluorouracil, oxaliplatin, and leucovorin; 5-FU, 5-fluorouracil; GI,
gastrointestinal; HIF, hypoxia-inducible factor; iNOS, inducible nitric oxide synthase; IR, immunoreactive; nNOS, neuronal
nitric oxide synthase; NF-κB, nuclear factor-κB; NHMRC, National Health and Medical Research Council; NO, nitric oxide;
OCT-1, organic cation transporter-1; OXL, oxaliplatin; PARP, poly(ADP)-ribose polymerase, ROS, reactive oxygen species;
SC, short contraction; SNP, sodium nitroprusside; SP-1, specificity protein-1; STAT1, signal transducer and activator of
transcription 1, VAChT, vesicular acetylcholine transferase.
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INTRODUCTION
Colorectal cancer (CRC) is a significant contributor to cancer
related mortality, resulting in more than 1 million deaths
annually (World Health Organization, 2011; Ferlay et al.,
2015). Due to its asymptomatic nature, approximately
60% of CRC sufferers are diagnosed at or beyond stage
III and a positive prognosis is heavily dependent upon
chemotherapeutic treatment (Siegel et al., 2014). For
several decades after its discovery, the antimetabolite 5-
fluorouracil (5-FU) was the only available chemotherapeutic
agent shown to improve 12-month survival rates in CRC
patients. To date, 5-FU remains the backbone of CRC therapy
(Goldberg, 2005), and when administered in combination
with oxaliplatin and leucovorin (FOLFOX), or irinotecan
and leucovorin (FOLFIRI), comprises one of the most
successful treatment regimens for CRC (Liang et al., 2010;
Ziauddin et al., 2010).
Over the past 30 years important modulation strategies have
been developed to increase anti-cancer activity and overcome
clinical resistance associated with 5-FU therapy. However, an
array of side-effects including stomatitis, esophago-pharyngitis,
alopecia, hematopoietic depression, fever, cardiotoxicity,
neurotoxicity, diarrhea, nausea, and vomiting persist as major
dose-limiting toxicities (Curreri et al., 1958; Diasio and Harris,
1989; Kennedy, 1999). Gastrointestinal side-effects in particular
are prevalent in patients receiving dual administration of 5-FU
and leucovorin with 15–20% suffering severe diarrhea as a result
of lower gastrointestinal tract toxicity (Buroker et al., 1994;
Fata et al., 1999).
It has been suggested that 5-FU-induced gastrointestinal
dysfunction results from inflammation, epithelial degradation,
and intestinal ulceration triggering intestinal mucositis (Duncan
and Grant, 2003). However, a recent study undertaken by our
group, showed that acute intestinal inflammation observed at
day 3 is resolved by day 7 but gastrointestinal dysfunction
persists throughout the course of treatment (McQuade
et al., 2016b). Our findings highlight inflammation-induced
myenteric neuronal loss as a potential contributing factor
to persistent 5-FU-induced gastrointestinal dysfunction
(McQuade et al., 2016b). It has been shown that inflammatory
cells liberate ROS at the site of inflammation leading to
oxidative stress (Biswas, 2016), and initiate intracellular
signaling cascades that enhance pro-inflammatory gene
expression (Anderson et al., 1994; Flohé et al., 1997).
5-FU-induced apoptosis is correlated with intracellular
oxidative stress in many cell types (Hosokawa et al., 2007;
Lamberti et al., 2012) and we have shown that oxaliplatin-
induced oxidative stress is correlated with neuronal loss
(McQuade et al., 2016a).
The cytoprotective agent BGP-15 (C14H22N4O2 2HCl)
has demonstrated neuroprotective efficacy in animal models
of chemotherapy-induced peripheral neurotoxicity (Bardos
et al., 2003). Our recent work has shown that BGP-15 co-
treatment alleviates neuropathy and gastrointestinal dysfunction
associated with oxaliplatin administration (McQuade et al.,
2018). Given that 5-FU-induced inflammation was resolved
by day 7, but all other changes persisted long-term, we
investigated the effects of in vivo long-term BGP-15 co-
treatment with 5-FU. In this study we examined (i)
in vivo gastrointestinal transit and emptying, (ii) fecal
water content, (iii) colonic inflammation, (iv) ex vivo
colonic motility functions, (v) neuronal mitochondrial
superoxide and cytochrome c levels in myenteric ganglia,
and (vi) the total number of myenteric neurons, and
subpopulations of inhibitory and excitatory neurons. We
aimed to determine the effect of 5-FU treatment on these




All procedures were approved by the Victoria University
Animal Experimentation Ethics Committee and performed
in accordance with the guidelines of the National Health
and Medical Research Council (NHMRC) Australian
Code of Practice for the Care and Use of Animals for
Scientific Purposes.
Animals
Male Balb/c mice aged 6–8 weeks (18–25 g) supplied by
the Animal Resources Centre (Perth, Australia) were used
for the experiments. Mice had free access to food and
water and were kept under a 12-h light/dark cycle in
a well-ventilated room at an approximate temperature of
22◦C. Mice were acclimatized for at least 5 days and
up to 7 days prior to the commencement of in vivo
intraperitoneal injections of chemotherapy. A total of 40 mice
were used for this study.
Intraperitoneal Injections
Mice received intraperitoneal injections of 5-FU (23 mg/kg)
(Sigma-Aldrich, Australia), with or without BGP-15 (15 mg/kg)
(N-Gene R&D Inc., United States) three times a week via
a 26-gauge needle as previously described (McQuade et al.,
2016a, 2018; McQuade, 2017). 5-FU and BGP-15 were
dissolved in 100% DMSO (Sigma-Aldrich, Australia) to
make 1 M L−1 stock solution refrigerated at −20◦C. The
stock was then defrosted and diluted with sterile water to
make 0.1 M L−1 (10% DMSO) solutions for intraperitoneal
injections. The dose of 5-FU was calculated to be equivalent
to standard human dose per body surface area (Reagan-
Shaw et al., 2008). Sham-treated mice received 10% DMSO
in sterile water via intraperitoneal injection three times
a week via a 26-gauge needle. A separate cohort of mice
received BGP-15 (15 mg/kg) alone via intraperitoneal injection
three times a week via a 26-gauge needle (McQuade, 2017).
The injected volumes were calculated according to body
weight; the maximum volume did not exceed 200 µL
per injection. At the conclusion of treatment, mice were
euthanized via cervical dislocation at either 3, 7, or 14 days
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after the first injection, and the colons were collected for
in vitro experiments.
Assessment of Mitochondrial Superoxide
Production
MitoSOXTM Red M36008 (Invitrogen, Australia), was used to
visualize mitochondrially derived superoxide in wholemount
preparations of myenteric ganglia of the colon. Freshly excised
distal colon preparations were dissected to expose myenteric
plexus. Preparations were incubated in oxygenated physiological
saline with MitoSOXTM Red M36008 (5 µM) at a constant
temperature of 37◦C for 40 min with gentle agitation. Tissues
were washed (2 × 30 min) with oxygenated physiological saline
(composition in mM: NaCl 118, KCl 4.6, CaCl2 3.5, MgSO4
1.2, NaH2PO4 1, NaHCO3 25, D-Glucose 11; bubbled with
95% O2 and 5% CO2) and fixed in 4% paraformaldehyde
(1.3 M) overnight at 4◦C. The following day, tissues were
washed (2 × 30 min) with physiological saline and mounted
on glass slides with DAKO fluorescent mounting medium for
imaging under a Nikon Eclipse Ti laser scanning confocal
microscope (Nikon, Japan). All images were captured at
identical acquisition exposure-time conditions, calibrated to
standardized minimum baseline fluorescence, converted to
binary and changes in fluorescence from baseline were measured
in arbitrary units (arb. units) using Image J software (NIH,
MD, United States). The corrected total fluorescence was
calculated as previously described (Burgess et al., 2010) in
32 5 µm × 5 µm boxes within myenteric ganglia from




Mitochondrial membrane potential changes in cells can be
detected with the use of the cationic, lipophilic dye JC-10. In
normal cells, JC-10 concentrates in the mitochondrial matrix
where it forms red fluorescent aggregates (JC aggregates).
In contrast, apoptotic cells stain in green fluorescent color
(JC monomeric form) due to the JC-10-labeled release of
cytochrome c diffusing out of the mitochondria as a result
of mitochondrial depolarization and increased permeability.
A JC-10 fluorescent mitochondrial membrane potential
microplate assay kit (Abcam, MA, United States) was used
to detect mitochondrial membrane potential changes and the
release of cytochrome c from damaged mitochondria in the
myenteric ganglia of the colon. Freshly excised distal colon
preparations from DMSO and 5-FU-treated mice were bathed
in oxygenated physiological saline and dissected to expose
the myenteric ganglia. Immediately following dissection,
preparations were incubated for 20 min with 500 µL of JC-
10 dye solution (buffer A) and gently agitated at a constant
temperature of 37◦C. After 20 min, 500 µL of buffer B
solution was added to tissue preparations and allowed to
incubate for another 20 min with constant agitation at a
constant temperature of 37◦C. Immediately following the final
incubation, tissues were mounted on glass slides with DAKO
fluorescent mounting medium for imaging under a Nikon




Colon segments (2–3 cm) were placed in oxygenated
phosphate-buffered saline (PBS) (pH 7.2) containing nicardipine
(3 µM) (Sigma-Aldrich, Australia) for 20 min to inhibit
smooth muscle contractions. They were then cut open along
the mesenteric border, cleared of their contents, maximally
stretched and dissected mucosa up to expose the myenteric
plexus attached to the longitudinal muscle layer. Tissues were
fixed with Zamboni’s fixative (2% formaldehyde and 0.2%
picric acid) overnight at 4◦C. Preparations were cleared of
fixative by 3 × 10 min washes with DMSO (Sigma-Aldrich,
Australia) followed with 3 × 10 min washes with PBS. Fixed
tissues were stored at 4◦C in PBS for a maximum of 5 days
(McQuade, 2017).
Wholemount preparations were incubated with 10%
normal donkey serum (Chemicon, United States) for 1 h
at room temperature, then washed (2 × 5 min) with PBS
and incubated with primary antibodies against β Tubulin III
(βTubIII) (chicken, 1:1000, Abcam, MA, United States), nNOS
(goat, 1:500, Abcam, MA, United States), and choline acetyl
transferase (ChAT) (goat, 1:200, Abcam, MA, United States)
overnight at 4◦C. Tissues were then washed in PBS (3 × 10 min)
before incubation with species-specific secondary antibodies
labeled with different fluorophores: donkey anti-chicken
Alexa 594 (1:200, Jackson ImmunoResearch Laboratories,
PA, United States) and donkey anti-goat Alexa 488 (1:200,
Jackson ImmunoResearch Laboratories, PA, United States)
for 2 h at room temperature. Wholemounts were given
3 × 10 min final washes in PBS and mounted on glass slides
using fluorescence mounting medium (DAKO, Australia)
(McQuade, 2017).
Immunohistochemistry in Cross Sections
Colon sections (1–2 cm) were placed in oxygenated PBS
containing nicardipine (3 µM) (Sigma-Aldrich, Australia) for
20 min to inhibit smooth muscle contractions. Samples were
cut open along the mesenteric border, cleared of their contents,
and pinned mucosa up without stretching. Tissues were fixed
with Zamboni’s fixative overnight at 4◦C. Preparations were
cleared of fixative by washing 3 × 10 min with DMSO
(Sigma-Aldrich, Australia) followed by 3 × 10 min washes
with PBS. After washing, tissues were embedded in 100%
OCT and frozen using liquid nitrogen (LN2) and isopentane
(2-methyl butane) and stored in −80◦C freezer. Tissues were
cut at 20 µm section thickness using a Leica CM1950 cryostat
(Leica Biosystems, Germany), adhered to slides and allowed
to rest for 30 min at room temperature before processing
(McQuade, 2017).
Cross section preparations were incubated with 10% normal
donkey serum (Chemicon, United States) for 1 h at room
temperature. Tissues were then washed (2 × 5 min) with
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PBS and incubated with primary antibody against CD45 (rat,
1:500, BioLegend, Australia) overnight at 4◦C. Sections were
then washed in PBS (3 × 10 min) before incubation with
secondary antibody labeled with fluorophore donkey anti-rat
Alexa 488 (1:200, Jackson ImmunoResearch Laboratories, PA,
United States) for 2 h at room temperature. The sections
were given 3 × 10 min final washes in PBS and then
cover-slipped using fluorescence mounting medium (DAKO,
Australia). Sections were viewed under a Nikon Eclipse Ti
laser scanning confocal microscope (Nikon, Japan), whereby
eight randomly chosen images from each preparation were
captured with a 20× objective and processed using NIS Elements
software (Nikon, Japan). The number of CD45+ IR cells
was quantified within a 2 mm2 area in every colonic section
(McQuade, 2017).
Imaging
Three dimensional (z-series) images of wholemount preparations
were taken using a Nikon Eclipse Ti laser scanning microscope
(Nikon, Japan), eight randomly chosen images from each
preparation were captured with a 20× objective and
processed using NIS Elements software (Nikon, Japan).
The number of βTubIII, nNOS, and ChAT IR neurons
was quantified in the myenteric ganglia within a 2 mm2
area of each preparation. Z-series images were taken at a
step size of 1.75 µm (1600 × 1200 pixels). All slides were
coded and analyzed blind (McQuade et al., 2016a, 2018;
McQuade, 2017).
Gastrointestinal Transit
Gastrointestinal transit was studied by X-ray before the
first treatment (day 0) and after 3, 7, and 14 days of
5-FU± BGP-15 treatment. The contrast agent, 0.4 mL of
suspended barium sulfate (X-OPAQUE-HD, 2.5 g/mL), was
administered via oral gavage. Prior to performing X-ray
imaging, animals were trained/conditioned for oral gavage
using a non-irritating substance 0.9% w/v saline (volume
0.1–0.4 ml); this was repeated at least three times with
each animal with at least 24 h between each training
(McQuade, 2017). Radiographs of the gastrointestinal tract were
performed using a HiRay Plus Porta610HF X-ray apparatus
(JOC Corp., Kanagawa, Japan; 50 kV, 0.3 mAs, exposure time
60 ms). Mice were immobilized in the prone position by
placing them inside a transparent plastic restraint tube with
a partly open front side for breathing, which comfortably
restrains animal movement essential for maximum of 1–
2 min for successful X-ray imaging. The training/conditioning
with restraint was achieved by placing the restrainer into
the mouse cages for at least 24 h prior to the X-ray
procedure. X-rays were captured using Fujifilm cassettes
(24 × 30 cm) immediately after administration of barium
sulfate (T0) then every 5 min for the first hour, every
10 min for the second hour, and then every 20 min
through to 360 min (T360). Animals were closely monitored
during and after all procedures. Images were developed via
a Fujifilm FCR Capsula XLII and analyzed using eFilm
4.0.2 software. Speed of gastrointestinal transit was calculated
as time in minutes taken to reach each region of the
gastrointestinal tract (stomach, small intestines, caecum, and
large intestines). Organ emptying was calculated as the time taken
for complete barium emptying from specific gastrointestinal
regions (stomach, small intestines) (Cabezos et al., 2008, 2010;
Girón et al., 2015).
Colonic Motility Experiments
The entire colon was removed from mice and set up in
organ-bath chambers to record motor patterns in vitro (Wafai
et al., 2013). Briefly, the colon was placed into warmed (35◦C),
oxygenated physiological saline until the fecal pellets were
expelled. The empty colon was cannulated at both ends and
arranged horizontally in organ-bath chambers. The proximal end
of the colon was connected to a reservoir containing oxygenated
physiological saline to maintain intraluminal pressure. The
distal end was attached to an outflow tube that provided a
maximum of 2 cm H2O back-pressure. Organ baths were
continuously superfused with oxygenated physiological saline
solution and preparations were left to equilibrate for 30 min.
Contractile activity of each segment was recorded with a
Logitech Quickcam Pro camera positioned 7–8 cm above the
preparation. Videos (2 × 15 min) of each test condition
were captured and saved in avi format using VirtualDub
software (version 1.9.11) (McQuade et al., 2016a, 2018;
McQuade, 2017).
CMMCs were defined as propagating contractions directed
from the proximal to the distal end of the colon which traveled
more than 50% of the colon length (Roberts et al., 2007,
2008; McQuade et al., 2016b; McQuade, 2017). Contractions
that propagated less than 50% colon length were considered
to be SCs. Another form of incomplete contraction was
identified as FCs occurring simultaneously at different parts
of the colon rather than propagating over the length of the
colon (McQuade et al., 2016b). Recordings were used to
construct spatiotemporal maps using in-house edge detection
software (Gwynne et al., 2004). Spatiotemporal maps plot
the diameter of the colon at all points during the recording
allowing contractile motor patterns to be analyzed with Matlab
software (version 12).
Fecal Water Content
Mice were single housed in cages without bedding or food
with free access to water for 20 min on days 3, 7, and 14 of
treatment, between 9 and 10 am. Feces were collected for analysis.
Wet weight of fecal pellets was measured immediately upon
pellet expulsion. Pellets were then dehydrated for 72 h at room
temperature prior to measurement of the dry weight. Water
content was calculated as the difference between the wet weight
and dry weight (McQuade, 2017).
Statistical Analysis
Data were assessed using two-way ANOVA, Welch’s
two-tailed t-test and Student’s two-tailed t-test. Analyses
were performed using Graph Pad Prism (Graph Pad
Software Inc., CA, United States). Data are presented
as mean ± standard error of the mean (SEM). Value
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differences were considered statistically significant
at P < 0.05.
RESULTS
Co-administration of BGP-15 With 5-FU
Delays Gastrointestinal Transit
To determine the effects of 5-FU treatment with and without
BGP-15 on gastrointestinal transit, a series of radiographic images
were used to track barium sulfate through the gastrointestinal
tract at day 3, 7, and 14 following treatment with DMSO, BGP-15,
5-FU, or 5-FU+BGP-15. The speed of barium movement was
calculated by tracing barium entry from one part of the
gastrointestinal tract to the next.
After 3 days of 5-FU administration, movement of barium
to the caecum and colon, gastric emptying, intestinal emptying
and pellet formation occurred significantly faster when compared
to DMSO-treated mice (Supplementary Figures S1A–E and
Supplementary Table S1). Treatment with BGP-15 alone
significantly sped up movement of barium to the caecum;
but had no effect on the speed of barium movement within
the colon, or on gastric emptying, intestinal emptying or
pellet formation when compared to DMSO-treated mice
(Supplementary Figures S1A–E and Supplementary Table S1).
When compared to 5-FU-treated mice, BGP-15 treatment did
not alter movement of barium to the caecum, but significantly
delayed movement of barium in the colon and delayed
gastric emptying, intestinal emptying and pellet formation
(Supplementary Figures S1A–E and Supplementary Table S1).
When given together with 5-FU, BGP-15 treatment significantly
delayed movement of barium to both the caecum and colon
as well as delaying gastric emptying and pellet formation when
compared to 5-FU-treated mice (Supplementary Figures S1A–E
and Supplementary Table S1). When compared to the
DMSO-treated mice, there was no significant differences in
gastric emptying, intestinal emptying or pellet formation in
5-FU+BGP-treated mice (Supplementary Figures S1A–E and
Supplementary Table S1).
After 7 days of 5-FU administration, movements of barium
within the colon, gastric emptying, intestinal emptying and
pellet formation were all significantly delayed when compared
to DMSO-treated mice (Supplementary Figures S2A–E and
Supplementary Table S2). When administered with 5-FU,
BGP-15 treatment had no effect on the movement of barium in
the caecum and colon, intestinal emptying or pellet formation
but did significantly delay gastric emptying when compared to
DMSO-treated mice. When compared to 5-FU-treated mice,
5-FU+BGP-15-treated mice had significantly faster barium
movement through the colon, but not the caecum, and
pellet formation occurred significantly faster, albeit gastric, and
intestinal emptying were not different (Supplementary Figures
S2A–E and Supplementary Table S2). Treatment with BGP-15
alone significantly sped up the movement of barium within
caecum as well as pellet formation but delayed gastric emptying
and intestinal emptying when compared to DMSO-treated mice
(Supplementary Figures S2A–E and Supplementary Table S2).
Whilst BGP-15 appears to restore some level of normality
to gastrointestinal transit at both day 3 (Supplementary
Figure S1B) and 7 (Supplementary Figure S2B), when
given in combination with 5-FU, BGP-15 treatment did not
alleviate 5-FU induced gastrointestinal transit delays at day 14
(Figures 1A–E and Supplementary Table S3). After 14 days
of 5-FU administration, movement of barium in the colon,
gastric emptying, intestinal emptying and pellet formation were
significantly delayed when compared to DMSO-treated mice
(Figures 1A–E and Supplementary Table S3). No significant
differences were found when comparing movement of barium
within the caecum and colon, gastric emptying, intestinal
emptying or pellet formation in 5-FU+BGP-15 to 5-FU-
treated mice (Figures 1A–E and Supplementary Table S3).
Treatment with BGP-15 alone sped up the movement of
barium within the caecum as well as pellet formation when
compared to DMSO-treated mice but delayed gastric emptying
and had no effect on intestinal emptying (Figures 1A–E
and Supplementary Table S3). When compared to 5-FU-
treated mice, movement of barium in the caecum and colon,
intestinal emptying and pellet formation was significantly
faster in BGP-15-treated mice, while no significant difference
in gastric emptying was found. Similar to 5-FU treatment,
combined 5-FU+BGP-15 delayed the speed of barium
movement in the colon and delayed the speed of pellet
when compared to DMSO-treated mice (Figures 1A–E and
Supplementary Table S3).
Colonic Fecal Water Content Changes
Following 5-FU ± BGP-15 Administration
To further define the clinical symptoms resulting from
5-FU ± BGP-15 administration, fresh fecal pellets were collected
from all mice on days 3, 7, and 14 of treatment and dehydrated
for 72 h. Fecal water content was subsequently calculated as the
difference between wet and dry pellet weight and is presented as
proportion of the total wet weight.
No significant difference in fecal water content were found at
day 3 or day 7 when comparing 5-FU to DMSO-treated mice
(Figures 2A,B and Supplementary Table S4), however, at day 14
fecal water content was significantly increased in 5-FU-treated
mice when compared to DMSO (P < 0.01, Figure 2C and
Supplementary Table S4). Treatment with BGP-15 alone had no
effect on fecal water content at any time point when compared
to either DMSO or 5-FU-treated mice (Figures 2A–C and
Supplementary Table S4). When given in combination with
5-FU, BGP-15 significantly increased fecal water content at
day 7 (P < 0.01) and day 14 (P < 0.05) when compared to




To investigate the effects of BGP-15 on 5-FU-induced colonic
inflammation, immune cell infiltration in the colon was
analyzed (Figure 3). Immune cells in colonic cross sections
were labeled with a pan leukocyte marker anti-CD45 antibody
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FIGURE 1 | Gastrointestinal transit time, gastric, and intestinal emptying following repeated in vivo 5-FU ± BGP-15 administration at day 14. Representative X-ray
images obtained from mice 5–210 min after intragastric barium sulfate (0.4 mL and 2.5 mg/mL) following 14 days of DMSO, 5-FU, BGP-15, and 5-FU+BGP-15
administration (A). Time (min) taken for barium sulfate to reach the stomach, small intestines, caecum, and large intestines at 7 days following DMSO, 5-FU,
BGP-15, and 5-FU+BGP-15 administration (B). Time (min) taken for complete emptying of barium from the stomach (C). Time (min) taken for complete emptying of
barium from the small intestines (D). Time (min) taken to form first pellet at 14 days following DMSO, 5-FU, BGP-15, and 5-FU+BGP-15 administration (E). Data
represented as mean ± SEM. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001 significantly different to DMSO. ††††P < 0.0001 significantly different to 5-FU.
#P < 0.05, ###P < 0.001, ####P < 0.0001 significantly different to BGP-15 (n = 5 mice/group).
(Supplementary Figure S3) following 3, 7, and 14 days
of DMSO (Figures 3A–A”), 5-FU (Figures 3B–B”), BGP-15
(Figures 3C–C”), and 5-FU+BGP-15 treatments (Figures 3D–
D”). Total numbers of CD45 positive cells were counted within a
2 mm2 area.
A significant increase in the number of CD45 positive
cells was found in the colon following 3 days of 5-FU
administration (98 ± 7 cells/2 mm2, P < 0.001) when
compared to DMSO-treated mice (51 ± 4 cells/2 mm2)
(Figure 3E). BGP-15 treatment alone significantly increased the
number of CD45 positive cells in the colon when compared to
DMSO-treated mice at day 3 (83 ± 1 cells/2 mm2, P < 0.0001)
(Figure 3E). When given with 5-FU, BGP-15 decreased the
number of CD45 cells in the colon at day 3 (72 ± 2 cells/2 mm2)
when compared to 5-FU-treated mice (P < 0.0001), but this was
still significantly greater than in DMSO (P < 0.001) (Figure 3E).
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FIGURE 2 | Water content following in vivo 5-FU ± BGP-15 administration.
Fecal water content calculated as the difference between the wet weight and
dry weight following 3 days (A), 7 days (B), and 14 days (C) treatment with
DMSO, 5-FU, BGP-15, and 5-FU+BGP-15 treatment. Data represented as
mean ± SEM. ∗∗P < 0.01 significantly different to DMSO group. †P < 0.05,
††P < 0.01, significantly different to 5-FU (n = 5 mice/group).
The number of CD45 positive cells was unchanged after 7
(51 ± 4 cells/2 mm2) and 14 (53 ± 4 cells/2 mm2) days of
5-FU treatment compared to DMSO (day 7 DMSO: 46 ± 3
cells/2 mm2, day 14 DMSO: 49 ± 3 cells/2 mm2) (Figures 3F,G).
BGP-15 treatment alone significantly increased the number of
CD45 positive cells in the colon at day 7 (83 ± 1 cells/2 mm2,
P< 0.0001) and 14 (82± 1 cells/2 mm2, P< 0.01) (Figures 3F,G).
When given with 5-FU, BGP-15 significantly increased the
number of CD45 positive cells at day 7 (85 ± 8 cells/2 mm2)
compared to both DMSO-treated (P < 0.01) and 5-FU-treated
mice (P < 0.05) (Figures 3F,G). Similarly, this treatment
significantly increased the number of CD45 positive cells at day
14 (107 ± 8 cells/2 mm2), compared to both DMSO-treated
(P < 0.01) and 5-FU-treated mice (P < 0.01) (Figures 3F,G).
Co-administration of BGP-15 With 5-FU
Exacerbates 5-FU-Induced Colonic
Dysmotility
To investigate effects of BGP-15 co-treatment on colonic motility,
excised colons (n = 5 mice/group) were studied in organ bath
experiments at day 14 of 5-FU treatment with and without
BGP-15. Analysis of spatiotemporal maps from 5-FU-treated
mice (Figures 4A–D) showed a significant increase in the
total number of contractions compared to DMSO-treated mice
(Figure 4E and Supplementary Table S5). BGP-15 treatment
alone did not affect the total number of contractions compared to
DMSO-treated mice (Figure 4E and Supplementary Table S5).
When BGP-15 was given in combination with 5-FU, the total
number of contractions was further increased when compared
to DMSO, BGP-15 and 5-FU-treated mice (Figure 4E and
Supplementary Table S5).
Treatment with 5-FU significantly decreased the proportion
and frequency of CMMCs when compared to DMSO-treated
mice (Figures 4F, 5A and Supplementary Table S5). BGP-15
treatment alone did not alter the proportion or frequency of
CMMCs from DMSO (Figures 4F, 5A and Supplementary Table
S5). When BGP-15 was given with 5-FU, it further reduced
the proportion and frequency of CMMCs when compared to
DMSO, BGP-15, and 5-FU-treated mice (Figures 4F, 5A and
Supplementary Table S5).
Treatment with 5-FU significantly increased the proportion
or frequency of SCs when compared to DMSO-treated mice
(Figures 4G, 5B and Supplementary Table S5). BGP-15
treatment alone did not alter the proportion or frequency of
SCs from DMSO (Figures 4G, 5B and Supplementary Table
S5). 5-FU+BGP-15 treatment significantly increased both the
proportion and frequency of SCs when compared to DMSO
and BGP-15 treated mice (Figures 4G, 5B and Supplementary
Table S5). When compared to 5-FU-treated mice, 5-FU+BGP-
15 treatment further increased the frequency of SCs, but
the proportion of SCs was unchanged (Figures 4G, 5B and
Supplementary Table S5).
Treatment with 5-FU significantly increased the proportion
and frequency of FCs when compared to DMSO-treated mice
(Figures 4H, 5C and Supplementary Table S5). BGP-15
treatment alone did not alter the proportion or frequency
of FCs from DMSO (Figures 4H, 5C and Supplementary
Table S5). 5-FU+BGP-15 significantly increased the proportion
and frequency of FCs compared to DMSO-treated mice
(Figures 4H, 5C and Supplementary Table S5) and further
significantly increased the frequency of FCs, but not the
proportion of FCs compared to 5-FU alone (Figures 4H, 5C and
Supplementary Table S5).
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FIGURE 3 | Inflammation in the colon repeated in vivo 5-FU ± BGP-15 administration. Cross sections of the colon labeled with antibody against CD45+ leukocytes
(green) following 3, 7, and 14 days of DMSO (A–A”), 5-FU (B–B”), BGP-15 (C–C”), and 5-FU+BGP-15 (D–D”) treatment, scale bar = 50 µm. Average number of
CD45+ cells in the colon was counted per 2 mm2 at 3 days (E), 7 days (F), and 14 days (G) in DMSO, 5-FU, BGP-15, and 5-FU+BGP-15-treated mice. Data
represented as mean ± SEM. ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001 significantly different to DMSO, †P < 0.05, ††P < 0.01, ††††P < 0.0001 significantly
different to 5-FU (n = 5 mice/group).
Co-administration of BGP-15 With 5-FU
Increases MitoSOX Fluorescence and
Cytochrome c Release in the Myenteric
Plexus
To evaluate production of ROS following long-term
5-FU ± BGP-15 treatment, the myenteric plexus in colon
samples collected at day 14 were probed with a fluorescent
mitochondrial superoxide marker MitoSOXTM Red M36008
(n = 5 mice/group) (Figures 6A–D). Decreased MitoSOX
fluorescence was found in the myenteric plexus of the distal
colon from 5-FU-treated mice (16.9 ± 1.08 arbitrary units)
compared to DMSO-treated animals (22.5 ± 2.08 arbitrary
units, P < 0.05) (Figure 6E). Treatment with BGP-15 alone
(20.7 ± 1.47 arbitrary units) had no effect on MitoSOX
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FIGURE 4 | Colonic motility following repeated in vivo 5-FU ± BGP-15 administration. Representative spatiotemporal maps generated from digital video recordings
of colonic motility following 14 days of DMSO (A), 5-FU (B), BGP-15 (C), and 5-FU+BGP-15 (D) administration. Each contraction can be seen as a reduction in the
gut width (red), while relaxation as an increase in the gut width (blue). Colonic migrating motor complexes (CMMCs) propagate >50% of the colon length, short
contractions (SCs) propagate <50% of the colon length and fragmented contractions (FCs) are interrupted by period(s) of relaxation during contraction. Total number
of contractions including all types of contractile activity in the colons from DMSO, 5-FU, BGP-15, and 5-FU+BGP-15 administration (E). The proportion of CMMCs
to the total number of contractions (F). The proportion of SCs to the total number of contractions (G). The proportion of FCs to the total number of contractions (H).
Data represented as mean ± SEM. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001, significantly different to DMSO group. †P < 0.05, ††P < 0.01,
††††P < 0.0001, significantly different to 5-FU group. #P < 0.05, ###P < 0.001, ####P < 0.0001, significantly different to BGP-15 (n = 5 mice/group).
fluorescence when compared to DMSO-treated mice (Figure 6E).
When given with 5-FU, BGP-15 significantly increased MitoSOX
fluorescence (38.5 ± 3.33 arbitrary units) when compared to
DMSO-treated, BGP-15-treated and 5-FU-treated mice (P< 0.01
for all) (Figure 6E).
Diffusion of cytochrome c out of the mitochondria in
the myenteric plexus as a result of mitochondrial membrane
depolarization and increased permeability can be measured
via fluorescence (green) of monomeric JC-10. To evaluate
production of monomeric JC-10 following long-term
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FIGURE 5 | Frequency of different contractions following repeated in vivo
5-FU ± BGP-15 administration. Number of CMMCs per 15 min in the colons
from DMSO, 5-FU, BGP-15, and 5-FU+BGP-15 administration (A). Number
of SCs per 15 min in the colons from DMSO, 5-FU, BGP-15, and
5-FU+BGP-15 administration (B). Number of FCs per 15 min in the colons
from DMSO, 5-FU, BGP-15, and 5-FU+BGP-15 administration (C). Data
represented as mean ± SEM. ∗∗P < 0.01, ∗∗∗∗P < 0.0001 significantly
different to DMSO group. †P < 0.05 significantly different to 5-FU group.
#P < 0.05, ##P < 0.01 significantly different to BGP-15 (n = 5 mice/group).
5-FU± BGP-15 treatment, colon samples collected at day
14 were probed with the fluorescent marker JC-10 (n = 5
mice/group) (Figures 6F–I). No significant difference in
JC-10 fluorescence was found in the myenteric plexus of the
distal colon from 5-FU-treated mice (8.6 ± 1.51 arbitrary
units) compared to DMSO-treated animals (9.5 ± 0.96
arbitrary units) (Figure 6J). Treatment with BGP-15 alone
(11.3 ± 1.24 arbitrary units) had no effect on JC-10 fluorescence
when compared to DMSO-treated mice (Figure 6J). When
given with 5-FU, BGP-15 significantly increased JC-10
fluorescence (18.4 ± 2.38 arbitrary units) when compared
to each of DMSO, BGP and 5-FU-treated mice (P < 0.05 for
all) (Figure 6J).
Co-treatment of BGP-15 With 5-FU Does
Not Attenuate 5-FU-Induced Enteric
Neuronal Loss, but Causes Changes in
Cholinergic and Nitrergic Neuronal
Populations
To investigate any changes to the total number of myenteric
neurons, wholemount preparations of day 14 colon were labeled
with a pan neuronal marker anti-βTub III for neuronal cell
counting within a 2 mm2 area in DMSO, 5-FU, BGP-15, and
5-FU+BGP-15-treated mice (n = 5 mice/group).
Repeated in vivo administration of 5-FU induced myenteric
neuronal loss (5-FU 1073 ± 19 neurons/area; DMSO 1221 ± 40
neurons/area, P < 0.0001). BGP-15 alone did not affect the
number of myenteric neurons (1214 ± 41 neurons/area)
compared to DMSO. When given with 5-FU, BGP-15 had
no effect on the number of myenteric neurons (1076 ± 60
neurons/area) when compared to 5-FU-treated mice, which
remained significantly reduced compared to DMSO-treated
mice (P < 0.0001).
To determine if BGP-15 co-treatment was associated with
changes in specific subpopulations of myenteric neurons, the
average number and proportion of ChAT-IR and nNOS-IR
motor and interneurons were analyzed in the colon from
DMSO, 5-FU, BGP-15, and 5-FU+BGP-15-treated mice (n = 5
mice/group) (Figures 7A–D).
The number of ChAT-IR neurons in 5-FU-treated mice
was decreased (286 ± 6 neurons/area) when compared to
DMSO-treated mice (313 ± 4 neurons/area, P < 0.001)
(Figure 7E). However, when the proportion of ChAT-IR
neurons to the total number of cells was analyzed, no
difference in the proportion of ChAT-IR neurons was found
in 5-FU-treated mice (27 ± 0.6%) compared to DMSO-treated
mice (25 ± 0.1%) (Figure 7F). Treatment with BGP-15 alone
significantly decreased the number (137 ± 2 neurons/area)
of ChAT-IR neurons compared to DMSO and 5-FU treated
mice (P < 0.0001 for both), and the proportion (11 ± 0.4%)
of ChAT-IR neurons when compared to both DMSO-treated
mice and 5-FU-treated mice (Figure 7E, P < 0.001 for
both). When given in combination with 5-FU, BGP-15
significantly increased the number (615 ± 2 neurons/area)
and proportion (57 ± 4%) of ChAT-IR neurons compared
to DMSO, BGP-15, and 5-FU-treated mice (P < 0.0001
for all) (Figures 7E,F).
The number of nNOS-IR neurons in 5-FU-treated mice
was significantly decreased (311 ± 6) when compared to
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FIGURE 6 | Mitochondrial superoxide and mitochondrial membrane potential in the myenteric plexus following repeated in vivo 5-FU ± BGP-15 administration.
Fluorescent wholemount preparations of the myenteric plexus labeled with MitoSOXTM Red M36008 in the colons from DMSO (A), 5-FU (B), BGP-15 (C), and
5-FU+BGP-15-treated mice (D), scale bar = 50 µm. Quantification of the levels of MitoSOXTM Red M36008 production visualized by fluorescent probe in the
myenteric plexus in colonic preparations from DMSO, BGP-15, 5-FU, and 5-FU+BGP-15-treated mice (E). Fluorescent wholemount preparations of the myenteric
plexus labeled with monomeric JC-10 in the colons from DMSO (F), 5-FU (G), BGP-15 (H), and 5-FU+BGP-15-treated mice (I), scale bar = 50 µm. Quantification of
the levels of monomeric JC-10 production visualized by fluorescent probe in the myenteric plexus in colonic preparations from DMSO, BGP-15, 5-FU, and
5-FU+BGP-15-treated mice (J). Data represented as mean ± SEM significantly different to 5-FU group. Data represented as mean ± SEM. ∗P < 0.05, ∗∗P < 0.01
significantly different to DMSO group. †P < 0.05, ††P < 0.01 significantly different to 5-FU group. #P < 0.05, ##P < 0.01 significantly different to BGP-15 (n = 5
mice/group).
DMSO-treated mice (391 ± 9 neurons/area, P < 0.01, n = 5
mice/group) (Figures 7G,H,K). However, no difference in the
proportion of nNOS-IR neurons was found when comparing
5-FU-treated (29 ± 0.4%) to DMSO-treated mice (32 ± 1%)
(Figure 7L). Treatment with BGP-15 alone significantly increased
the number of nNOS-IR neurons (497 ± 27 neurons/area)
when compared to both DMSO-treated mice (P < 0.05) and
5-FU-treated mice (P < 0.0001) as well as the proportion
of nNOS-IR neurons (41 ± 1.5%) when compared to both
DMSO-treated mice and 5-FU-treated mice (P < 0.001 for
both) (Figure 7L). When given with 5-FU, BGP-15 significantly
increased the number (636 ± 35 neurons/area) and proportion
(59 ± 2%) of nNOS-IR neurons compared to DMSO-
treated, BGP-15-treated and 5-FU-treated mice (P < 0.0001
for all) (Figures 7I–L).
DISCUSSION
In this study, the effect of BGP-15 and 5-FU co-treatment
on myenteric neurons and gastrointestinal functions was
examined. Results indicate that BGP-15 co-treatment increased
mitochondrial superoxide production and mitochondrial
depolarization in the myenteric plexus increased the number
and proportion of ChAT-IR and nNOS-IR neurons in the
myenteric plexus. BGP-15 co-treatment failed to protect against
5-FU-induced neuronal loss and significantly increased the
inflammation in colonic cross sections, as measured by the
presence of CD45 positive cells. Although BGP-15 co-treatment
delayed the onset of gastrointestinal symptoms at days 3 and
7, it had no effect on 5-FU-induced changes in gastrointestinal
transit speed, gastric emptying, intestinal emptying or pellet
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FIGURE 7 | Effect of repeated in vivo 5-FU ± BGP-15 administration on average number and proportion of ChAT and nNOS-IR myenteric neurons. Wholemount
preparations of ChAT-IR myenteric neurons (green) in the myenteric plexus of the distal colon in DMSO (A), 5-FU (B), BGP-15 (C), and 5-FU+BGP-15-treated (D)
mice, scale bar = 50 µm. Average number of ChAT-IR neurons in the colon was counted per 2 mm2 at 14 days in DMSO, 5-FU, BGP-15, and
5-FU+BGP-15-treated mice (E). Proportion of ChAT-IR neurons to the total number of βTub III-IR myenteric neurons in the colon was counted at 14 days in DMSO,
BGP-15, 5-FU, and 5-FU+BGP-15-treated mice (F). Wholemount preparations of nNOS-IR neurons (green) in the myenteric plexus of the distal colon in DMSO (G),
5-FU (H), BGP-15 (I), and 5-FU+BGP-15-treated (J) mice, scale bar = 50 µm. Average number of nNOS-IR neurons in the colon was counted per 2 mm2 at
14 days in DMSO, 5-FU, BGP-15, and 5-FU+BGP-15-treated mice (K). Proportion of nNOS-IR neurons to the total number of βTub III-IR myenteric neurons in the
colon was counted at 14 days in DMSO, 5-FU, BGP-15, and 5-FU+BGP-15-treated mice (L). Data represented as mean ± SEM. ∗P < 0.05, ∗∗P < 0.01,
∗∗∗P < 0.001, ∗∗∗∗P < 0.0001, significantly different to DMSO group. †††P < 0.001, ††††P < 0.0001, significantly different to 5-FU group. ###P < 0.001,
####P < 0.0001, significantly different to BGP-15 (n = 5 mice/group).
formation at the end of treatment. BGP-15 co-treatment
exacerbated 5-FU-induced colonic dysmotility at day 14 by
reducing the number and proportion of CMMCs and increasing
the number and proportion of FCs. These changes were
correlated with increased fecal water content, which may be
indicative of diarrhea.
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Results of the current study have indicated that BGP-15
co-treatment had no beneficial effect on 5-FU-induced delays
in gastrointestinal transit, gastric emptying, intestinal emptying,
or pellet formation at end of treatment, and is not an
appropriate neuroprotective agent when given with 5-FU. This
is in contrast to our previous findings where co-treatment of
BGP-15 with oxaliplatin improved oxaliplatin-induced delays in
gastrointestinal transit, intestinal emptying, and pellet formation
(McQuade et al., 2018). These conflicting results may, in part, be a
consequence of exacerbation of inflammation experienced during
5-FU administration (McQuade et al., 2016b), and/or in vivo
interactions between 5-FU and BGP-15.
The cytoprotective agent BGP-15 is a multi-target compound
known to inhibit PARP 1. Although pharmacological PARP
inhibition has yielded promising results for neuroprotection
in animal models of ischemia, traumatic brain injury, diabetic
neuropathy, chemotherapy-induced peripheral neuropathy
(Plaschke et al., 2000; LaPlaca et al., 2001; Obrosova et al.,
2008; Lupachyk et al., 2011; Brederson et al., 2012; Ta et al.,
2013), findings from the current study demonstrate that
BGP-15 treatment alone and in combination with 5-FU induces
colonic inflammation at all time points. PARP1 regulates the
expression of various proteins associated with inflammation at
the transcriptional level, including iNOS, intercellular adhesion
molecule-1 and major histocompatibility complex class II via
its activity on NF-κB (Hiromatsu et al., 1992; Pacher and Szabo,
2008; Peralta-Leal et al., 2009). Whilst there is some contention
as to the role of PARP in inflammation, at a cellular level,
PARP1 has been implicated in the activation and progression
of inflammation (Ba and Garg, 2011). Reduction of functional
PARP1 has been found to decrease the expression of several
pro-inflammatory mediators, including cytokines, chemokines,
adhesion molecules, and enzymes (Peralta-Leal et al., 2009).
Furthermore, it has also been reported that PARP1 actively
regulates other transcription factors implicated in cellular stress
and inflammation, including AP-1, OCT-1, SP-1, HIF, and
STAT1 (Peralta-Leal et al., 2009). Given the vast and varied
roles of PARP in inflammatory mediation, inhibition of PARP
by BGP-15 may contribute to the detrimental effects of BGP-15
treatment in our study.
The results of the current study demonstrate that
inflammation following combined 5-FU+BGP-15 treatment,
but not 5-FU treatment alone, is associated with increased
mitochondrial superoxide production in the myenteric plexus
observed at day 14. It is well known that inflammatory cells
liberate a number of ROS at the site of inflammation leading
to exaggerated oxidative stress (Biswas, 2016), whilst ROS
can initiate intracellular signaling cascades that enhance
pro-inflammatory gene expression (Anderson et al., 1994; Flohé
et al., 1997). Although at physiological concentrations ROS may
function as signaling molecules that regulate cell growth, cellular
adhesion, differentiation, senescence, and apoptosis (Thannickal
and Fanburg, 2000; Dröge, 2002), chronic or prolonged ROS
production is central to the progression of inflammatory
conditions (Mittal et al., 2014). The intricate balance between cell
death and cell survival is largely modulated by intracellular ROS
generation (Mittal et al., 2014).
Results of the current study have demonstrated that
co-administration of BGP-15 with 5-FU, but not 5-FU alone,
is associated with mitochondrial depolarization leading to
cytochrome c release indicative of apoptotic cell death. This,
in turn, was correlated with neuronal loss in 5-FU-treated
mice that was not alleviated by co-treatment with BGP-15.
While this is the first study to investigate the effect of
BGP-15 in combination with 5-FU treatment on the myenteric
plexus, our previous work investigating combined oxaliplatin
and BGP-15 treatment has demonstrated that BGP-15 reduced
markers of oxidative stress and improved neuronal survival
at the level of the myenteric plexus (McQuade et al., 2018).
The underlying mechanisms responsible for these opposing
results is unknown but may be related to chemotherapeutic
mechanism of action or in vivo drug interaction. Previous
studies investigating the effects of a PARP inhibitor rucaparib
in combination with 5-FU in the treatment of acute myeloid
leukemia and acute lymphoblastic leukemia found that 5-FU and
rucaparib synergize to induce a massive DNA damage ex vivo,
measured by expression of phosphorylated histone (γH2AX)
(Falzacappa et al., 2015). This “hyperdamage,” however, was
not induced in PARP inhibition associated with administration
of an oxaliplatin predecessor, platinum compound cisplatin
(Falzacappa et al., 2015), suggesting specificity in the combination
of PARP inhibition and 5-FU potentially resulting from in vivo
drug interactions. The underlying mechanism responsible for
the synergistic 5-FU+BGP-15 enteric neuronal damage in the
current study is not known but may be due to loss of functional
PARP in various pathways or to the way that 5-FU exerts its
cytotoxicity, which is poorly understood.
We have previously shown that long-term 5-FU
administration has no effect on the proportion of either
ChAT or nNOS-IR neurons in the myenteric plexus (McQuade
et al., 2016b). However, in the present study BGP-15 treatment
alone and in combination with 5-FU significantly influenced
the proportion of both ChAT and nNOS-IR neurons. Following
BGP-15 treatment the proportion of nNOS-IR neurons was
increased by 10% when compared to DMSO-treated mice,
combined 5-FU+BGP-15 treatment further increased the
proportion of nNOS-IR neurons by 28% when compared to
5-FU-treated mice. Whilst this increase in nNOS-IR neurons
was accompanied by a concurrent loss in proportion of ChAT-IR
neurons in BGP-15-treated mice (15% loss when compared
to DMSO), interestingly in 5-FU+BGP-15-treated mice the
proportion of ChAT-IR neurons was simultaneously increased
alongside nNOS-IR neurons. These changes may imply: (1)
that there is upregulation of ChAT and nNOS-IR in neurons
that already express both, (2) that there has been an important
change in neurochemical phenotype, or (3) both. It has been
established that neurons can alter their chemical phenotype
under pathological conditions (Sharkey and Kroese, 2001; Csillik
et al., 2003; Ekblad and Bauer, 2004; Kaleczyc et al., 2007). Change
in either neuropeptide expression or neurochemical phenotype
could result in disrupted motility, due to effects on interneurons,
intrinsic primary afferent neurons or motor neurons.
The proportion of ChAT-IR neurons in DMSO-treated
mice reported in this study (26%) is lower than previously
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described in Balb/c mice (55%) (Sang and Young, 1998). Whilst,
these discrepancies in the proportion of ChAT-IR neurons
may be attributed to investigative and/or analytical errors,
it has previously been noted that ChAT immunoreactivity
is often centered in the cytoplasm with weak cell surface
immunoreactivity, resulting in faint labeling across some
ChAT-IR neurons (Furness et al., 2004). It is possible that
ineffective labeling of ChAT has resulted in a lower than
normal proportion of ChAT-IR neurons in the cohort of mice
used in this study, however, the proportion of ChAT reported
in this study is in line with our previously published work
(McQuade et al., 2016b). Regardless, whether the increase in
ChAT-IR in 5-FU+BGP-15-treated mice is associated with de
novo synthesis of ChAT and what the exact functional phenotype
of these neurons is requires further investigation. Further studies
investigating the co-localization of nNOS and ChAT-IR neurons
in 5-FU+BGP-15-treated mice need to be undertaken.
Loss of neurons in both 5-FU-treated and BGP-15 co-treated
mice was associated with chronic colonic dysmotility. Moreover,
co-treatment of BGP-15 with 5-FU exacerbated 5-FU-induced
colonic dysmotility by reducing the number and proportion
of CMMCs and increasing the number and proportion of
FCs. Although this is in contrast to our previous data
demonstrating that BGP-15 co-treatment with oxaliplatin
alleviated oxaliplatin-induced colonic dysmotility (McQuade
et al., 2018), the current findings are in line with our studies
demonstrating that loss of enteric neurons negatively affects
patterns of colonic motility (McQuade et al., 2016a, 2018). Our
previous data indicate that 5-FU-induced myenteric neuronal
loss of approximately 12% severely impacted patterns of colonic
motility, significantly reducing the frequency and proportion
of CMMCs whilst increasing frequency and proportion of
SCs and FCs (McQuade et al., 2016a). In the current study
the overall proportion of CMMCs was reduced by 93% in
5-FU+BGP-15-treated mice when compared to 5-FU-treated
mice, whilst the proportion of SCs and FCs were increased by
86 and 175%, respectively. Short and FCs play a vital role in
the construction of productive motor patterns in the healthy
intestine (Gwynne et al., 2004). In the current study these altered
patterns of colonic motility in 5-FU+BGP-15-treated mice
were associated with increased fecal water content. Although
pellet formation was delayed in 5-FU+BGP-15-treated mice,
it is possible that mucosal damage and the consequential
inflammatory response reduced the absorptive capacity in the
colon. Furthermore, heightened cholinergic innervation may
have contributed to increased intestinal secretion resulting in
increased fecal water expulsion (Fung et al., 2018).
Although previously BGP-15, has shown cytoprotective
potential (Racz et al., 2002; Bardos et al., 2003; Sarszegi et al.,
2012) as well as chemo-potentiating capacity, in animal models
of whole body radiation, death of PARP−/− mice has been
linked to gastrointestinal failure (Herceg and Wang, 2001). When
compared to wild type controls all PARP−/− mice died within
10 days of treatment with lethality associated with massive
cell death and hemorrhage in small intestinal villi resulting
in potential changes to intestinal absorption and sections
and systemic dehydration in mice (Herceg and Wang, 2001).
Moreover, PARP−/− mice had severe hemorrhage in the
glandular stomach (Masutani et al., 2000).
CONCLUSION
In conclusion, this study is the first to demonstrate that
BGP-15 exacerbated colonic inflammation and triggered the
production of mitochondrial superoxide in 5-FU-treated mice.
These changes were not beneficial to neuronal survival and
exacerbated 5-FU-induced colonic dysfunction, resulting in
increased fecal water content, indicative of diarrhea. Although
PARP1 inhibition has shown both chemotherapeutic and
neuroprotective potential in previous studies, it is clear
from the work presented here that the effectiveness of
BGP-15 application is heavily reliant on drug combination.
Inflammation induced by 5-FU may also be a significant
factor in estimating the prognostic outcome of BGP-15
application. Further studies need to be undertaken investigating
the relevance of inflammation in mediating BGP-15 efficacy
and understanding the relationship between oxidative stress
and inflammation.
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FIGURE S1 | Gastrointestinal transit time, gastric and intestinal emptying following
repeated in vivo 5-FU ± BGP-15 administration at day 3. Representative X-ray
images obtained from mice 5–210 min after intragastric barium sulfate (0.4 mL
and 2.5 mg/mL) administration following 3 days of DMSO, 5-FU, BGP-15, and
5-FU+BGP-15 administration (A). Time (min) taken for barium sulfate to reach the
stomach, small intestines, caecum, and large intestines in at 3 days following
DMSO, 5-FU, BGP-15, and 5-FU+BGP-15 administration (B). Time (min) taken
for complete emptying of barium from the stomach (C). Time (min) taken for
complete emptying of barium from the small intestines (D). Time (min) taken to
form first pellet at 3 days following DMSO, 5-FU, BGP-15, and 5-FU+BGP-15
administration (E). Data represented as mean ± SEM. ∗P < 0.05, ∗∗P < 0.01,
∗∗∗P < 0.001, ∗∗∗∗P < 0.0001 significantly different DMSO group. †P < 0.05,
††P < 0.1, †††P < 0.001, ††††P < 0.0001, significantly different to 5-FU.
#P < 0.05, significantly different to BGP-15 (n = 5 mice/group).
FIGURE S2 | Gastrointestinal transit time, gastric, and intestinal emptying
following repeated in vivo 5-FU ± BGP-15 administration at day 7. Representative
X-ray images obtained from mice 5–210 min after intragastric barium sulfate
(0.4 mL and 2.5 mg/mL) administration following 7 days of DMSO, 5-FU, BGP-15,
and 5-FU+BGP-15 administration (A). Time (min) taken for barium sulfate to reach
the stomach, small intestines, caecum, and large intestines at 7 days following
DMSO, 5-FU, BGP-15, and 5-FU+BGP-15 administration (B). Time (min) taken
for complete emptying of barium from the stomach (C). Time (min) taken for
complete emptying of barium from the small intestines (D). Time (min) taken to
form first pellet at 7 days following DMSO, 5-FU, BGP-15, and 5-FU+BGP-15
administration (E). Data represented as mean ± SEM. ∗P < 0.05, ∗∗∗P < 0.001,
∗∗∗∗P < 0.0001, significantly different to DMSO group. †††P < 0.001, significantly
different to 5-FU. ##P < 0.01, ####P < 0.0001, significantly different to BGP-15
(n = 5 mice/group).
FIGURE S3 | Negative control for immunolabeling with CD45 antibody. Labeling
with Alexa-Fluor 488 resulted in no visible stain at baseline fluorescence (A), at
50% maximum fluorescence labeling with Alexa-Fluor 488 resulted in some
autofluorescence, however no discernible CD45+ cells were present (A’).
Representative slide of CD45+ labeling acquired at 50% maximum fluorescence
for comparison (B).
TABLE S1 | Speed of transit and emptying following 3 days repeated in vivo
5-FU ± BGP-15 administration.
TABLE S2 | Speed of transit and emptying following 7 days repeated in vivo
5-FU ± BGP-15 administration.
TABLE S3 | Speed of transit and emptying following 14 days repeated in vivo
5-FU ± BGP-15 administration.
TABLE S4 | Fecal water content following 14 days repeated in vivo
5-FU ± BGP-15 administration.
TABLE S5 | Colonic motility following 14 days repeated in vivo
5-FU ± BGP-15 administration.
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